Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

ABSTRACT:

SUBMITTER: Holthof LC 

PROVIDER: S-EPMC7012462 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature